Phase I Dose-Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) for Patients With BCG-Resistant Localized Transitional Cell Carcinoma of the Bladder.
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2015
At a glance
- Drugs Tremelimumab (Primary) ; BCG
- Indications Bladder cancer
- Focus Adverse reactions
- 24 Mar 2011 Planned End Date changed from 1 May 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 06 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 06 Feb 2010 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.